Glioblastoma heterogeneity at single cell resolution
David Eisenbarth1, Y Alan Wang2
1The Brown Center for Immunotherapy, Department of Medicine, Melvin and Bren Simon Comprehensive Cancer Center, Indiana University School of Medicine, Indianapolis, IN, 46202, USA. deisenb@iu.edu.
Oncogene
|June 5, 2023
Summary
Glioblastoma (GBM) exhibits significant cellular diversity, hindering effective treatment. Understanding this heterogeneity at the single-cell level is crucial for developing new therapeutic strategies against this deadly brain cancer.
Area of Science:
- Oncology
- Cancer Biology
- Genomics
Background:
- Glioblastoma (GBM) is a highly lethal and treatment-resistant brain cancer.
- Tumor heterogeneity, encompassing diverse cell states and microenvironments, is a primary cause of therapeutic resistance.
- Existing classification methods struggle to capture the full complexity of GBM subtypes.
Purpose of the Study:
- To provide an overview of the multifaceted nature of Glioblastoma heterogeneity.
- To discuss recent advancements in single-cell technologies for elucidating GBM complexity.
- To connect cellular network understanding with therapeutic resistance in GBM.
Main Methods:
- Review of recent scientific literature on Glioblastoma heterogeneity.
- Analysis of single-cell sequencing data and its implications.
- Discussion of intrinsic and extrinsic factors contributing to GBM diversity.
Main Results:
- Single-cell technologies reveal extensive cellular diversity within GBM.
- GBM heterogeneity differs significantly between treatment-naïve and experienced, as well as newly diagnosed and recurrent tumors.
- Specific cell states correlate with varying sensitivities to therapies.
Conclusions:
- Understanding the intricate cellular network of GBM heterogeneity is essential for developing novel treatment approaches.
- Single-cell analysis offers unprecedented insights into GBM biology and therapeutic vulnerabilities.
- Targeting GBM heterogeneity holds promise for overcoming treatment resistance.
